News
ITRMF
0.030
-57.39%
-0.040
Iterum Therapeutics shares face Nasdaq delisting after minimum bid price breach
Reuters · 12h ago
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 16h ago
BUZZ-U.S. STOCKS ON THE MOVE -Shake Shack, Perpetua, Caribou Biosciences
Reuters · 16h ago
Gold Gains Over 1%; FactSet Research Raises FY2026 Outlook
Benzinga · 17h ago
Dow Jumps 400 Points; TD Synnex Posts Upbeat Earnings
Benzinga · 19h ago
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 21h ago
ITERUM THERAPEUTICS PLC - TRADING OF COMPANY’S ORDINARY SHARES ON NASDAQ WILL BE SUSPENDED AT THE OPENING OF BUSINESS ON APRIL 1, 2026
Reuters · 22h ago
Iterum Therapeutics Cut to Neutral From Buy by HC Wainwright & Co.
Dow Jones · 1d ago
What's Going On With Iterum Therapeutics Stock Monday?
Benzinga · 1d ago
HC Wainwright & Co. Downgrades Iterum Therapeutics to Neutral
Benzinga · 1d ago
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 1d ago
Dow Gains 200 Points; Bullfrog AI Shares Jump
Benzinga · 1d ago
Iterum Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
TipRanks · 1d ago
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 1d ago
Iterum Therapeutics Files Wind Up Petition; Shares Shoot In Pre-market
NASDAQ · 1d ago
Weekly Report: what happened at ITRM last week (0323-0327)?
Weekly Report · 1d ago
Why PMGC Holdings Shares Are Trading Higher By Over 100%; Here Are 20 Stocks Moving Premarket
Benzinga · 1d ago
Iterum Therapeutics Initiates Liquidation Proceedings and Leadership Exit
TipRanks · 4d ago
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 4d ago
BUZZ-U.S. STOCKS ON THE MOVE-Entergy, IDEX Corp, Quanta Services
Reuters · 4d ago
More
Webull provides a variety of real-time ITRMF stock news. You can receive the latest news about Iterum Therapeutics Plc through multiple platforms. This information may help you make smarter investment decisions.
About ITRMF
Iterum Therapeutics plc is a clinical-stage pharmaceutical company. The Company develops differentiated anti-infectives. It offers ORLYNVAH (sulopenem in an oral tablet formulation) medicine, which is an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women. Sulopenem is a potent, thiopenem antibiotic delivered intravenously which is active against bacteria that belong to the group of organisms known as gram-negatives and cause urinary tract and intra-abdominal infections. The Company operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.